Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat Phase 2a in CKD Anemia
NCT01381094Phase 2Completed
- Sponsor
- Akebia Therapeutics
- Start
- Jun 2011
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vadadustat in anemia of chronic kidney disease (CKD-A) (5 arms), sponsored by Akebia Therapeutics. Primary endpoint: Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6). Started Jun 2011; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT01381094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381094.